Incyte and Merck work together on NSCLC trial; later expanded to include additional cancers
Incyte Corp. and Merck & Co. Inc. will conduct a Phase I/II trial on a combination of Incyte's INCB24360 with Merck's MK3475 for metastatic and recurrent non-small cell lung cancer and other advanced tumors.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com